The short answer
Getting hormone therapy online is legitimate, and it is often faster than waiting months for a gynaecology appointment. But the service has to do five things: connect you with a clinician licensed in the state you are physically located in, take a history that actively screens for the contraindications printed on the drug's own label, prescribe an FDA-approved product filled by a licensed pharmacy, tell you your prescriber's name and license, and see you again. If any of those five is missing, you are not buying care. You are buying a product with a prescription stapled to it.
Disclosure: this page is not sponsored, contains no affiliate or paid links, and names no telehealth provider as a recommendation. VidaBeacon does earn commissions from some links elsewhere on this site; no online menopause service has paid for coverage here or for placement in our comparison pages. Our job on this page is to make you a harder customer to fool.
What a legitimate online menopause service actually does
1. Matches you with a clinician licensed where you are. Under US telehealth rules, care is generally treated as delivered where the patient is sitting, so the prescriber usually must be licensed in your state (or covered by an interstate compact or a state telehealth registration). This is why real services ask for your address before they ask about hot flashes. A service that never asks where you are physically located cannot be doing this correctly.
2. Takes a history that can produce a "no." A real intake is looking for reasons not to prescribe. The contraindications section of a generic estradiol transdermal system label on DailyMed (Sandoz authorized generic, label revision 12/2023, checked 13 July 2026) lists them plainly: undiagnosed abnormal genital bleeding; breast cancer or a history of breast cancer; estrogen-dependent neoplasia; active DVT or pulmonary embolism, or a history of either; active arterial thromboembolic disease such as stroke or heart attack, or a history of either; hepatic impairment or disease; protein C, protein S or antithrombin deficiency and other known thrombophilic disorders; and known hypersensitivity, anaphylactic reaction or angioedema to the product. A good intake asks about every one of these in language you can actually answer. A bad one asks how bad your hot flashes are and takes your card.
3. Prescribes an FDA-approved product. Estradiol patches, gels, sprays, tablets and vaginal products, plus micronised progesterone, are FDA-approved: made to a tested standard, with a label you can read. Compounded creams, troches and pellets are not FDA-approved, which means they are not reviewed by the agency for safety, effectiveness or manufacturing quality. The National Academies, in its 2020 report on compounded bioidentical hormone therapy, concluded that use should be restricted to patients who cannot use an FDA-approved product — for example, a documented allergy to an ingredient in the approved version, or a dose or route that is simply not manufactured.
4. Names the prescriber. You should be able to see the name, credential and license number of the person who signed your prescription, and reach them with a question. "Our medical team" is not a name. Every state medical board runs a free license lookup.
5. Follows up. Hormone therapy is not a one-off transaction. Expect a check-in within the first few months, a defined route for what to do if you bleed, and a stated position on blood pressure, breast screening and re-evaluation over time.
The red flags
| Red flag | Why it matters |
|---|---|
| Questionnaire in, prescription out, minutes later | No opportunity to clarify a history. Contraindication screening only works if someone can ask you a follow-up question. |
| The business model is compounded pellets or custom creams | Not FDA-approved, so potency and absorption are not held to the standard a manufactured patch is. Pellets in particular cannot be removed once inserted. |
| Saliva or urine testing used to set your dose | The Menopause Society's 2022 hormone therapy position statement says salivary and urine hormone testing to determine dosing is unreliable and not recommended. |
| "Hormone balancing" / "optimizing your levels" | Marketing language, not a clinical target. Menopausal hormone therapy is prescribed to treat symptoms and, in some cases, to protect bone — not to hit a number on a printout. |
| No named prescriber | You cannot verify a license you cannot see. |
| Bleeding is not asked about — or is waved off | Undiagnosed abnormal genital bleeding is the first printed contraindication on the estradiol label. Missing it is not a small error. |
| Bundled supplements, "detox" kits, or a subscription you cannot cancel online | The margin is in the bundle, which tells you what the service is optimising for. |
| Testosterone offered casually as a first-line "energy" fix | ACOG notes there is no FDA-approved testosterone formulation for managing menopausal symptoms. It can be prescribed off-label after a shared decision, but that is a considered decision, not an upsell. |
The pellet problem, stated plainly
Compounded hormone pellets are implanted under the skin, usually in the hip, and release hormone over months. Two facts rarely appear in the marketing. First, they are compounded, so the dose is not standardised the way a manufactured patch is. Second — and this is the one to remember — a pellet cannot be taken back out. If the dose turns out to be too high, there is no equivalent of peeling off a patch or stopping a tablet. It runs its course, sometimes for months, along with whatever side effects the dose produces. ACOG's 2023 clinical consensus on compounded bioidentical menopausal hormone therapy says exactly this: citing the lack of safety data and the inability to remove the pellet, it recommends preparations other than pellet therapy for delivering testosterone. That asymmetry — an irreversible route for a therapy that usually needs adjusting — is why many menopause specialists will not use them.
None of this is an instruction to stop, start or switch anything; that is a conversation with your own prescriber, not a decision to make from a web page. It means the choice belongs to you and a clinician who can explain why an approved product would not work for you. Read more on the terminology in bioidentical hormones and bioidentical hormone myths.
Bleeding gets evaluated first. Not later.
This is the single most important line on this page. Any bleeding after menopause — a spot, a streak on paper, one episode a year ago — belongs in an evaluation before hormone therapy is started, not after. Postmenopausal bleeding is how endometrial cancer most often announces itself, and it is highly treatable when it is caught early. Starting estrogen first can muddy the picture and delay the answer, which is precisely why "undiagnosed abnormal genital bleeding" sits at the top of the contraindications list on the label. See postmenopausal bleeding for what an evaluation involves. If an online service shrugs at this, that is your answer about the service.
What the label says — and who decides your dose
Doses are public information; they are printed on the label. The generic estradiol transdermal system label on DailyMed, for instance, publishes six strengths — 0.025, 0.0375, 0.05, 0.06, 0.075 and 0.1 mg per day (checked 13 July 2026). That is what the label publishes. It is not a menu, and nothing on this page is a dosing instruction. Your prescriber selects the product, the route and the strength, based on your history, your symptoms and whether you still have a uterus. If you do have a uterus, systemic estrogen must be taken together with an adequate progestogen to protect the endometrium — unopposed estrogen raises the risk of endometrial cancer, which is why that boxed warning stays on estrogen-alone products.
Do not self-adjust your dose. Do not cut or split a patch, do not stretch a supply by skipping days, and do not double up after a missed dose — call the prescriber and ask what to do instead. A service that encourages any of that is not practising medicine. For how the routes differ, see HRT pills vs patches vs gels and estradiol.
One current wrinkle worth knowing. On 10 November 2025 the FDA told application holders it wanted the boxed warning on cardiovascular disease, breast cancer and probable dementia removed from menopausal hormone therapy products, while keeping the endometrial cancer boxed warning on systemic estrogen-alone products. On 12 February 2026 the FDA announced it had approved those labeling changes for a first group of six products — including Bijuva, Divigel, Cenestin, Enjuvia, Prometrium and Estring — and said 29 application holders had submitted proposed changes. The rest arrive product by product. When we checked DailyMed on 13 July 2026, a generic estradiol transdermal system label (Sandoz, revision 12/2023) still carried the old boxed warning text in full. So the leaflet in your box may lag the FDA's current position, and a service that quotes whichever version suits its pitch is doing marketing, not medicine.
Cost and coverage: the honest shape
We quote no prices on this page. A number we cannot verify on the day you read it is worse than no number at all — copays, cash prices and subscription fees all move, and we cannot see your plan. What we can give you is the shape of it, so you know what to ask.
Generic estradiol (patch or tablet) and generic micronised progesterone are among the cheapest FDA-approved routes and are commonly on plan formularies. Branded gels, sprays and combination products vary more. Compounded pellets and custom creams are typically cash-pay and usually not covered, and the insertion or consult fee is often billed separately from the product itself. Telehealth subscription fees are frequently not billable to insurance at all.
Ask your plan, in these words: "Is [exact product name and strength] on my formulary, what tier, what is my copay, and does it need prior authorization?" Ask the pharmacy: "What is the cash price if I don't use insurance?" — for generics, that is sometimes lower than the copay. Transparent-pricing pharmacies publish their prices publicly; check the number on the pharmacy's own page on the day you buy, because these change. Never misrepresent anything to an insurer — not your symptoms, not your diagnosis, not who the medication is for. If you are denied, ask for the denial reason in writing and for the appeal route; that is the legitimate path, and appeals succeed more often than people expect. Our cost and coverage estimator walks through the questions, and how much menopause care costs covers the wider picture.
The questions to ask before you pay
| Ask | A good answer sounds like |
|---|---|
| Who will prescribe for me, and are they licensed in my state? | A name, a credential, and a license number you can verify on your state board's site. |
| Will I speak to them — video, phone or asynchronous message? | Any of these can be legitimate, but there must be a real two-way exchange, not a form. |
| Are the products you prescribe FDA-approved, and which pharmacy fills them? | Named FDA-approved products, named licensed pharmacy. If the answer is "compounded," ask why, specifically, for me. |
| Do you prescribe pellets? What happens if the dose is wrong? | An honest service will tell you a pellet cannot be removed. That answer is the test. |
| Do you use saliva or urine hormone tests to set doses? | "No." Testing has a role in some situations, but not for dosing symptomatic menopausal women. |
| What is the total cost — consult, subscription, medication — and what recurs? | An itemised number, and a cancellation route you can use without a phone call. |
| What is the follow-up plan, and how do I reach a clinician if I bleed? | A scheduled check-in and a defined escalation path. |
| Will you send notes to my regular doctor? | Yes, on request. Care that refuses to talk to your other care is a silo, not a service. |
Take the answers, not the vibes. Our menopause and HRT telehealth comparison lays out how services differ on exactly these criteria — without ranking one as "best," and with no paid placement — and how to choose online menopause care goes deeper on evaluating a service.
When telehealth is not the right first step
Some situations call for an in-person evaluation, and most of them appear on the label as contraindications or cautions — which means a careful online service will route you to one rather than prescribe. Bring these to a clinician who can examine you:
- Any bleeding after menopause, or new heavy, prolonged or between-period bleeding in perimenopause. This gets evaluated first; it is a printed contraindication, not a formality.
- A personal history of breast cancer, endometrial cancer, or another hormone-sensitive tumour.
- A prior blood clot (DVT or PE), stroke, heart attack, or a known clotting disorder — including one in a close relative that has never been investigated.
- Hepatic impairment or active liver disease.
- A new breast lump, nipple discharge, or a mammogram you have been putting off.
- Chest pain, sudden shortness of breath, a swollen painful calf, sudden severe headache, or weakness on one side of the body — at any time, on or off hormone therapy. That is emergency care, now, not a message to a portal.
Contact your prescriber, rather than waiting for the next scheduled check-in, if you bleed on HRT and were not told to expect it, if you develop new migraines with aura, or if your blood pressure climbs. And if something feels wrong on hormone therapy, the answer is never to quietly change the dose yourself. Ask. That is what the follow-up is for.
Related: questions to ask your doctor about HRT, menopause hormone testing, hormone replacement therapy explained, and the wider menopause hub.
This article is information, not medical advice, and does not replace an evaluation by a clinician who knows your history. It contains no dosing instructions: only a prescriber who knows you can select, start, change or stop a hormone therapy dose.
